secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001493152-23-000844
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa appoints Sapirstein, Freitag, and Rupalla to board post-business combination
--------------------------------------------------------------------------------

- ZyVersa appoints James Sapirstein (FWBI CEO), Gregory Freitag (PDSB board), and Katrin Rupalla to its board effective Jan 5, 2023.
- Appointments fill three vacancies from the Dec 12, 2022 business combination with Larkspur Health Acquisition Corp.
- Sapirstein to serve on Compensation & Nominating Committees; receives $40k annual retainer plus $11.5k committee fees.
- Freitag to chair Audit and serve on Nominating Committee; receives $40k retainer plus $22.5k committee fees.
- Rupalla to chair Nominating Committee; receives $40k retainer plus $8k; all receive option grants under 2022 Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/0001493152-23-000844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223000844/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer